Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
mGFBJART4VmH8VeS
